Hair Health News : Good News for Those Who Want to Regrow Hair

A Smart + Strong Site
Subscribe to:
Real Health magazine
Join Real Health: Facebook Pinterest Twitter YouTube
Back to home » Hair Health News » February 2013
Quick Hair Links
Hair Health Facts
Talking Hair in RH Forums
Are you hair smart?
Take the quiz
How's your hair health?
Take the survey
Women's Hair Health:
Men's Hair Health:
Male Hair Issues
Razor Bumps
Children's Hair Health:
ABCs of Children's Hair Health
Puberty & Hair Care Chemicals
Other Hair Health:
Black Hair Growth
Organic Hair Care
Featured Products:
For Women
For Men
For Children

May 2015
March 2015
November 2014
May 2014
April 2014
March 2014
February 2014
December 2013
October 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
February 2010
May 2006


February 15, 2013

Good News for Those Who Want to Regrow Hair

An FDA-approved glaucoma drug named bimatoprost may be the answer to many who have lost precious strands and can’t get their hair to grow, according to a recent research report that appeared online in the FASEB Journal and reported by Science Daily.

For the study, researchers conducted tests on human cells and one on the skin of mice. For the human cell tests, scientists applied bimatoprost on hair follicles grown in an organ culture as well as those directly from the human scalp. Researchers found that the bimatoprost stimulated hair growth. In the third test, scientists applied the drug to bald spots on mice and this also resulted in hair growth.

“We hope this study will lead to the development of a new therapy for balding which should improve the quality of life for many people with hair loss,” said Valerie Randall, a researcher from the University of Bradford, in the United Kingdom.

Scientists were excited about the findings because bimatoprost is approved for human use and has a positive safety profile. The drug is currently the active ingredient in Latisse, a popular topical medication used to regrow eyelash hair. Some doctors have already begun using bimatoprost on patients who requested treatments.

The bad news is, bimatoprost ain’t cheap. A news report stated that a tiny 3 ml bottle of the drug costs $120.00 and lasts just two to three weeks. What's more, the drug still needs official studies so doctors can determine how to use it more effectively to treat patients fighting hair loss.

Hair growth can’t happen if you don’t have a healthy scalp. Click here to read more.


Search: Valerie Randall, FASEB Journal, glaucoma treatment, bimatoprost, hair growth, Latisse, hair loss, eyelash hair growth

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Real Health team review all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

Featured Video
In this video Kara Young, model and entrepreneur, talks with Real Health editor-in-chief Kate Ferguson about living with natural curly hair.
Real Health Hair Fun Fact
79% of Real Health visitors regularly buy some of their hair products at beauty supply stores.

[ about Smart + Strong | about Real Health | advertising | contact us | advertising policy ]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.